logo munafa.co.com

NEWS Gainers Losers
 Learn then Earn

 story : FDA advisory committee votes 10-8 in favor of ChemoCentryx's experimental drug; stock is down #FinanceUSA #StockMarketNEWS Shares of ChemoCentryx Inc. tumbled 61.7% in trading on Friday, the day

@stockMarketNEWS Mon 10 May, 2021

Posted in: #FinanceUSA #StockMarketNEWS

FDA advisory committee votes 10-8 in favor of ChemoCentryx's experimental drug; stock is down #FinanceUSA #StockMarketNEWS
Shares of ChemoCentryx Inc. tumbled 61.7% in trading on Friday, the day after a Food and Drug Administration advisory committee voted 10-8 that the benefits of the company's experimental autoimmune drug, avacopan, outweigh the risks. The mixed response from committee members followed critical words from the FDA earlier this week that had sent ChemoCentryx's stock diving. The company's stock this week was downgraded by Raymond James and Stifel Nicolaus, among others. Raymond James analyst Steven Seedhouse told investors that while he downgraded the stock to outperform, from strong buy, he still predicts a FDA approval by July 7 and a future blockbuster in avacopan, which is being evaluated as a treatment for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. "We're actually not changing our unadjusted avacopan estimates (~.9B peak unadjusted U.S. sales), only our probability of success (now at 50% vs. 100% prior)," he wrote. "Yes, we're calling this a pure coin flip between now and July 7." ChemoCentryx's stock is down 54.4% for the year, while the broader S&P 500 is up 11.8%.


Munafa USA Munafa India Munafa NSE


Report

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

 Learn then Earn
Back to top | Use Dark Theme